14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Issue 3 (September 2015) - Vansteenkiste, J.; Fehrenbacher, L.; Spira, A.I.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; Braiteh, F.; Yi, J.; He, P.; Kowanetz, M.; et al.